Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Special Report A Closer Look at Healthcare Sector Earnings: AZN vs. EW vs. ZBHAuthor: Nathan Reiff. First Published: 2/12/2026. 
Key Points - AstraZeneca, Edwards Lifesciences, and Zimmer Biomet all reported earnings on the same day, but with vastly different results.
- Of these, AstraZeneca's impressive oncology medicine sales growth stands out, having driven significant top-line growth.
- Edwards and Zimmer both saw notable successes in the latest quarter, but also face sizable challenges.
- Special Report: [Sponsorship-Ad-6-Format3]
More than a financial check-up, earnings for companies in the healthcare sector give investors a key window into a firm's pipeline and development progress. Even well-established, stable firms can surprise with growth after the release of a new blockbuster drug or medical device, and earnings periods are an opportunity for management to provide context beyond what investors might glean from FDA approvals or notices. When healthcare companies report on the same day, it can be a busy time for investors trying to sort noteworthy news and plan trades. On Feb. 10, 2025, three major names—AstraZeneca (NASDAQ: AZN), Edwards Lifesciences (NYSE: EW), and Zimmer Biomet (NYSE: ZBH)—reported full-year and Q4 2025 results. Below are highlights and takeaways for healthcare investors. AstraZeneca Firms Up Cancer Business in a Strong Overall Quarterly Performance I Called Black Monday. Now I'm Calling March 26!
I predicted the 1987 crash six weeks early. I called the fall of the Berlin Wall. I pinpointed the exact bottom in 2009.
Now I'm staking my reputation on March 26, 2026 - the day I believe Elon will announce the SpaceX IPO.
Bloomberg is calling it "the biggest listing of ALL TIME."
A $1.5 TRILLION valuation... the "wealth-building" moment of the decade.
Today, I'll show you how to get in before the big announcement. Click Here to See How to Secure Your "SpaceX Access Code" U.K.-based AstraZeneca finished 2025 reinforcing its position as a leading cancer-medicine provider, with oncology accounting for about 44% of product sales in the final quarter. Sales of oncology drugs such as Imfinzi and Enhertu grew as much as 48% year-over-year (YOY), helping drive total revenue up 8.6% to $58.7 billion for the quarter. After-tax profits rose alongside revenue, climbing to $10.2 billion from $7 billion in the year-ago quarter. The board declared a second interim dividend that was 7 cents higher than last year's. Investors also have more potential catalysts ahead as AstraZeneca advances dozens of drugs through clinical trials. Management said 20 Phase 3 readouts are expected in 2026, and the company anticipates solid increases in both total revenue and core earnings per share (EPS) for full-year 2026. In the hours after its strong earnings release, AZN shares rose nearly 3%. Although 10 of 11 analysts rate AZN a Buy or equivalent, some on Wall Street have questioned valuation — the consensus price target of $95.75 implies a potential decline of roughly 51% from current levels. TAVR Momentum Fuels Edwards Sales Growth, Though Investors Should Note Earnings and Margin Limitations Edwards makes replacement heart valves, monitoring systems and other surgical devices. Its Q4 2025 results were largely positive, with 13.3% YOY sales growth driven by strong transcatheter aortic valve replacement (TAVR) momentum and adoption of the latest SAPIEN valve. At the same time, adjusted EPS missed analyst expectations, and gross profit margin dipped 0.8% YOY. Despite those mixed signals, Edwards reiterated confidence in its prior 2026 outlook, which called for sales growth of 8%–10% YOY and EPS in the $2.90–$3.05 range. EW shares jumped above $80 in after-hours trading, roughly 4% higher following the announcement. About two-thirds of analysts covering EW rate the stock a Buy, and the consensus target of $96.77 implies roughly 25% upside from current levels. Orthopedic Demand Remains High, But Zimmer Faces Some Headwinds Zimmer Biomet, a maker of implants and systems for joint and bone disorders, saw its shares rise more than 3% in after-hours trading after reporting EPS of $2.42—$0.04 above consensus—and revenue of $2.2 billion, up nearly 11% YOY and slightly ahead of expectations. Persistent demand for orthopedic products supported both top- and bottom-line gains. The company is shifting to focus more on U.S. sales, which account for roughly 60% of its business. With insured patient utilization continuing to push upward, near-term demand for Zimmer's products is expected to remain strong. However, tariffs are likely to remain a headwind and could weigh on EPS and revenue in 2026. Management issued conservative guidance in the latest report, forecasting adjusted EPS of $8.30–$8.45 and free cash flow improvement of 8%–10%. Prior to the release, analysts were divided on Zimmer, with the company carrying an overall Hold rating despite roughly 15% projected upside.
| 
